Synthes-Stratec Joint Replacement Unit Locks Into Biomet Joint Venture
This article was originally published in The Gray Sheet
Executive Summary
Biomet Merck is looking to expand its 300-person European sales force as part of its acquisition of Synthes-Stratec's European artificial joint replacement business, announced Oct. 29